

10TH ANNUAL CALIFORNIA CANCER CONSORTIUM CONFERENCE

“Recent Advances and New Directions in Cancer Therapy”



August 8-10, 2014
The Westin Pasadena
Pasadena, CA

Presented by the California Cancer Consortium

University of California Davis Comprehensive
Cancer Center, Sacramento, CA

City of Hope Comprehensive Cancer Center
Duarte, CA

University of Southern California/
Norris Comprehensive Cancer Center
Los Angeles, CA

University of Pittsburgh Cancer Institute/UPMC
Pittsburgh, PA

Barbara Ann Karmanos Comprehensive Cancer
Center (Wayne State University), Detroit, MI

Penn State Hershey Cancer Institute
(Penn State University), Hershey, PA



Program Chairs:

Primo Lara, Jr., M.D. | Edward Newman, Ph.D.

Steering Committee:

Chandra Belani, M.D. | Edward Chu, M.D.
David Gandara, M.D. | Heinz-Josef Lenz, MD, Ph.D.
Patricia LoRusso, D.O. | Robert Morgan, M.D.

Sponsored by:
THE MEDICAL EDUCATOR CONSORTIUM



PROGRAM CHAIRS

Primo Lara, Jr., M.D.

Professor of Medicine
University of California Davis School of Medicine
Associate Director for Translational Research
University of California Davis Comprehensive Cancer Center

Edward Newman, Ph.D.

Associate Professor, Molecular Pharmacology
Co-director, Analytical Pharmacology Core Facility
City of Hope Comprehensive Cancer Center

STEERING COMMITTEE

Chandra Belani, M.D.

Miriam Beckner Distinguished Professor of Medicine
Penn State Milton S. Hershey Medical Center Deputy Director
Penn State Hershey Cancer Institute

Edward Chu, M.D.

Professor and Chief of Hematology/Oncology
University of Pittsburgh School of Medicine
Deputy Director, University of Pittsburgh Cancer Institute

David Gandara, M.D.

Professor of Medicine
University of California Davis School of Medicine
Senior Advisor to the Director
University of California Davis Comprehensive Cancer Center

Heinz-Josef Lenz, M.D., Ph.D.

Professor of Medicine and Preventive Medicine, Section Head of GI Oncology
University of Southern California, Keck School of Medicine
Associate Director for Clinical Research, University of Southern California Norris Comprehensive Cancer Center

Patricia LoRusso, D.O.

Professor of Medicine
Wayne State University School of Medicine
Director, Center for Experimental Therapeutics, Karmanos Cancer Institute

Robert Morgan, M.D.

Professor of Medicine
Co-director, Gynecological Cancers Program
City of Hope Comprehensive Cancer Center

DISTINGUISHED FACULTY

Leonard Appleman, M.D.

Assistant Professor
University of Pittsburgh School of Medicine
University of Pittsburgh Cancer Institute

Chandra Belani, M.D.

Miriam Beckner Distinguished Professor of Medicine
Penn State Milton S. Hershey Medical Center Deputy Director
Penn State Hershey Cancer Institute

Suzette Blanchard, Ph.D.

Assistant Professor and Senior Biostatistician
City of Hope Comprehensive Cancer Center

Alice Chen, M.D.

Senior Investigator
CTEP, National Cancer Institute

Helen Chew, M.D.

Professor of Medicine
University of California Davis School of Medicine

Diana Chingos, MS, MFA

Patient Advocate
University of Southern California and Young Survival Coalition

Tanya Dorff, M.D.

Assistant Professor
University of Southern California Keck School of Medicine
Norris Comprehensive Cancer Center

Anthony El-Khoueiry, M.D.

Assistant Professor
University of Southern California Keck School of Medicine
Norris Comprehensive Cancer Center

Stephen Forman, M.D.

Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation
Co-leader, Hematologic Malignancies Program
City of Hope Comprehensive Cancer Center

Paul Frankel, Ph.D.

Senior Biostatistician, Division of Biostatistics, Department of Information Sciences
Beckman Research Institute, City of Hope Comprehensive Cancer Center

Shirish Gadgeel, M.D.

Leader, Thoracic Oncology Multidisciplinary Team, Barbara Ann Karmanos Cancer Center
Associate Professor, Wayne State University School of Medicine

David Gandara, M.D.

Professor of Medicine, University of California Davis School of Medicine
Senior Advisor to the Director, University of California Davis Comprehensive Cancer Center

Susan Groshen, Ph.D.

Professor of Medicine and Director, Biostatistics Core
University Southern California Norris Comprehensive Cancer Center

Elisabeth Heath, M.D.

Associate Professor of Oncology, Wayne State University School of Medicine
Barbara Ann Karmanos Cancer Center

Brian Jonas, M.D., Ph.D.

Assistant Professor, University of California Davis School of Medicine
University of California Davis Comprehensive Cancer Center

Monica Joshi, M.D.

Assistant Professor
Penn State University Hershey School of Medicine, Penn State Hershey Cancer Institute

Karen Kelly, M.D.

Professor of Medicine, University of California Davis School of Medicine
Associate Director of Clinical Research, University of California Davis Comprehensive Cancer Center

Friedrich Knollman, M.D., Ph.D.

Professor of Clinical Radiology, University of California Davis School of Medicine

Marianna Koczywas, M.D.

Clinical Professor of Medicine
City of Hope Comprehensive Cancer Center

Primo Lara, Jr., M.D.

Professor of Medicine, University of California Davis School of Medicine
Associate Director for Translational Research, University of California Davis Comprehensive Cancer Center

Heinz-Josef Lenz, M.D., Ph.D.

Professor of Medicine and Preventive Medicine, Section Head of GI Oncology, University of Southern California, Keck School of Medicine
Associate Director for Clinical Research
University Southern California Norris Comprehensive Cancer Center

Tianhong Li, M.D., Ph.D.

Assistant Professor, University of California Davis School of Medicine
University of California Davis Comprehensive Cancer Center

Xin Liu, M.D.

Assistant Professor
Penn State University Hershey School of Medicine, Penn State Hershey Cancer Institute

Jeffrey Longmate, Ph.D.

Professor and Director, Division of Biostatistics, Department of Information Sciences
Beckman Research Institute, City of Hope Comprehensive Cancer Center

Patricia LoRusso, D.O.

Professor of Medicine, Wayne State University School of Medicine
Director, Center for Experimental Therapeutics
Barbara Ann Karmanos Cancer Institute

Philip Mack, Ph.D.

Associate Professor of Medicine, University of California Davis School of Medicine
Director
Cancer Molecular Pharmacology
University of California Davis Comprehensive Cancer Center

Kim Margolin, M.D.

Professor of Medicine
University of Washington School of Medicine
Fred Hutchinson Cancer Research Center
Seattle Cancer Care Alliance

Robert Morgan, M.D.

Professor of Medicine, Department of Medical Oncology and Therapeutics Research
Co-director, Gynecological Cancers Program
City of Hope Comprehensive Cancer Center

Edward Newman, Ph.D.

Associate Professor, Molecular Pharmacology
Co-director, Analytical Pharmacology Core Facility
City of Hope Comprehensive Cancer Center

Amit Oza, M.D.

Senior Staff Physician and Professor of Medicine
Princess Margaret Hospital, University of Toronto School of Medicine

Sumanta Pal, M.D.

Assistant Professor, Department of Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center

Philip Philip, M.D.

Professor of Medicine, Wayne State University School of Medicine
Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute

Jacek Pinski, M.D, Ph.D.

Associate Professor of Medicine
Co-director, Prostate Cancer Research Program
USC Norris Comprehensive Cancer Center

David Quinn, MBBS, Ph.D.

Associate Professor and Head, Section of GU Medical Oncology, USC Keck School of Medicine
Leader, Developmental Therapeutics Program
University of Southern California Norris Comprehensive Cancer Center

Karen Reckamp, M.D.

Co-director, Lung Cancer and Thoracic Oncology Program
Associate Professor, Department of Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center

Jonathan Riess, M.D.

Assistant Professor, University of California Davis School of Medicine
University of California Davis Comprehensive Cancer Center

Lynda Roman, M.D.

Associate Professor and Director
Division of Obstetrics and Gynecology
USC Keck School of Medicine
USC Norris Comprehensive Cancer Center

Thomas Semrad, M.D.

Assistant Professor, UC Davis School of Medicine
University of California Davis Comprehensive Cancer Center,

Tanya Siddiqi, M.D.

Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation
City of Hope Comprehensive Cancer Center

George Somlo, M.D.

Professor, Department of Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center

Timothy Synold, PharmD

Co-director, Analytical Pharmacology Core Facility
Associate Professor, Molecular Pharmacology
City of Hope Comprehensive Cancer Center

Ahmad Tarhini, M.D.

Associate Professor of Medicine, Clinical and Translational Science
University of Pittsburgh School of Medicine

Joseph Tuscano, M.D.

Professor of Medicine, University of California Davis School of Medicine
University of California Davis Comprehensive Cancer Center

Przemyslaw Twardowski, M.D.

Associate Professor, Department of Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center

Ulka Vaishampayan, M.D.

Associate Professor of Medicine
Wayne State University School of Medicine, Barbara Ann Karmanos Cancer Institute

“Recent Advances and New Directions in Cancer Therapy”

COURSE DESCRIPTION

This conference aims to provide up-to-date information to the clinician regarding new advances in cancer biology, diagnosis, and treatment. It will bring together respected opinion leaders, practicing clinicians and scientists engaged in clinical cancer research to discuss the latest cancer diagnostic and therapeutic advances. Topics focus on the major cancers and drug development areas, including signal transduction/CDK inhibition, angiogenesis inhibition, PI3K/mTOR inhibition, antibody-drug conjugates, and immunotherapy, among others. This annual conference also includes interactive roundtable discussion forums with participation of cancer care experts from the California Cancer Consortium, and features renowned professionals from academia, patient advocacy, government, payer, industry, and business realms of cancer care.

EDUCATIONAL OBJECTIVES

After participating in this educational activity, you should be able to:

- Identify signaling and immunotherapeutic pathways that are involved in the growth and metastases of many individual tumor types, and identify specific opportunities for therapeutic intervention.
- Describe recent advances in the molecular phenotyping of cancer and relate these to the optimal management of your patients with cancer.
- Based on recent clinical trials, assess the efficacy of novel therapeutic strategies in the treatment of your patients with cancer.
- Discuss the new and emerging clinical trial designs that can test and validate new therapeutic strategies for cancer patients.

TARGET AUDIENCE

This program will be of interest to medical oncologists, hematologists, surgical oncologists, radiation oncologists, diagnostic radiologists, pulmonologists, urologists, gastroenterologists, pathologists, fellow and resident trainees, advanced care practitioners, registered nurses, physician assistants, clinical research coordinators, biostatisticians, and others involved in oncologic drug development and clinical care.

NEEDS ASSESSMENT

This course was developed in cooperation with the academic faculty and scientists belonging to the California Cancer Consortium to provide an annual in-depth exposure and review of new advances in cancer drug development, biology,

biomarkers, diagnosis, and therapy. The agenda and format was specifically designed to address knowledge gaps identified from prior course participant evaluations and unsolicited comments from practicing oncologists (from private practice, academia) as well as scientists involved in cancer clinical trials. This area of knowledge will be best addressed by an in-depth conference on systemic therapy of malignancies (both solid and hematologic), with ample time provided for interaction by attendees with expert faculty. It is expected that this course will enhance the clinical competence of clinicians in managing the care of the cancer patient, and subsequently improve patient outcomes.

ACCREDITATION

The Medical Educator Consortium is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT HOURS

The Medical Educator Consortium designates this educational activity for a maximum of 15 *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

DISCLOSURE

The Medical Educator Consortium (MEC) adheres to the ACCME Standards for Commercial Support. All persons that will be in a position to control the content of the CME Activity are required to disclose all relevant financial relationships. Faculty disclosure forms outlining this information will be made available to all participants prior to educational activity. MEC has also implemented a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity.

NURSING CONTINUING MEDICAL EDUCATION

Continuing Medical Education is acceptable for meeting RN continuing education requirements, as long as the course is *AMA PRA Category 1 Credits*[™], and has been taken within the appropriate time frames.

gettyimages

CONFERENCE AGENDA

10th Annual California Cancer Consortium Conference "Recent Advances and New Directions in Cancer Therapy"

FRIDAY, AUGUST 8TH, 2014

9:30 am - 12:30 pm	Industry Advisory Board Block (by invitation only)
2:00 pm	Registration & Visit Exhibits
3:30 pm	Welcome and Introductions
3:35 pm	Pre-session Survey

Session 1: Inhibition of Signal Transduction and Angiogenesis Pathways Chairs: Primo Lara Jr., M.D., (UC Davis) and Edward Newman, Ph.D., (City of Hope)

3:40 pm	EGFR and Met Inhibitors: State of the Art Karen Reckamp, M.D., City of Hope
3:50 pm	Question-and-Answer Session
3:55 pm	PI3K/Akt and Related Pathways: Novel Therapeutics Leonard Appleman, University of Pittsburgh
4:05 pm	Question-and-Answer Session
4:10 pm	FGF and FGFR as Therapeutic Targets Thomas Semrad, M.D., UC Davis
4:20 pm	Question-and-Answer Session
4:25 pm	New Vascular/Angiogenesis -Targeted Therapies Tanya Dorff, M.D., USC
4:35 pm	Question-and-Answer Session
4:40 pm	mTOR inhibitors: Latest and Greatest Sumanta Pal, M.D., City of Hope
4:50 pm	Question-and-Answer Session
5:00 pm	Refreshment Break & Visit Exhibits

Session 2: Clinical Trial Design Chairs: Jeffrey Longmate, Ph.D., (City of Hope) and Paul Frankel, Ph.D., (City of Hope)

5:15 pm	Integration of New Clinical Trial Designs for Early Drug Development Suzette Blanchard, Ph.D., City of Hope
5:25 pm	Question-and-Answer Session
5:35 pm	Statistical Designs for Biomarker Development Susan Groshen, Ph.D., USC
5:45 pm	Question-and-Answer Session
5:55 pm	Rebiopsies and Serial Biopsies in Clinical Trials Diana Chingos, MS, MFA, USC
6:05 pm	Question-and-Answer Session
6:10 pm	Cancer Imaging in the Molecular-Targeted Era Friedrich Knollman, M.D., Ph.D. (UC Davis)
6:20 pm	Question-and-Answer Session
6:25 pm	Roundtable Discussion: Novel Paradigms in Early Drug Development Moderator: Jeffrey Longmate, Ph.D., City of Hope
	Participants: Edward Newman, Ph.D. Paul Frankel, Ph.D., Suzette Blanchard, Ph.D. Susan Groshen, Ph.D., David Gandara, M.D.
	Themes: (1) Phase 0 Trials (2) Molecular Enrichment Strategies (3) Cytostatic Therapy Assessment
6:45 pm	Question-and-Answer Session
6:50 pm	Post-session Survey
7:00 pm - 9:00 pm	Wine and Cheese Welcome Reception & Visit Exhibits

CONFERENCE AGENDA

SATURDAY, AUGUST 9TH, 2014

6:30 am	Registration, Refreshments & Visit Exhibits
7:15 am – 8:00am	Breakfast Symposia (non CME)
8:00 am	Introduction
8:05 am	Pre-session Survey

Session 3: Cancer Immunotherapy

Chairs: Chandra Belani, M.D., (Penn State) and Tianhong Li, M.D., Ph.D., (UC Davis)

8:10 am	Genetically Modified T Cells for Treatment of Cancer <i>Stephen Forman, M.D., City of Hope</i>
8:25 am	Question-and-Answer Session
8:30 am	PD-1 and PDL-1 Targeted Therapy <i>Karen Kelly, M.D., UC Davis</i>
8:40 am	Question-and-Answer Session
8:45 am	Vaccine and Dendritic Cell Approaches <i>Przemyslaw Twardowski, M.D., City of Hope</i>
8:55 am	Question and Answer
9:00 am	CTLA4 and other Novel Immunotherapeutic Approaches (IDO, etc) <i>Elisabeth Heath, M.D., Wayne State</i>
9:10 am	Question and Answer

Session 4: Lung Cancer

Chairs: Mariana Koczywas, M.D., (City of Hope) and Jonathan Riess, M.D., (UC Davis)

9:20 am	Linking Molecular Biology to Cancer Therapeutics in NSCLC <i>David Gandara, M.D., UC Davis</i>
9:40 am	Question-and-Answer Session
9:45 am	Squamous Cell Lung Cancer: Current and Future Directions <i>Chandra Belani, M.D., Penn State</i>
10:05 am	Question-and-Answer Session
10:10 am	Small Cell Lung Cancer: Emerging Therapeutics <i>Shirish Gadgeel, M.D., Wayne State</i>
10:20 am	Question and Answer
10:25 am	Refreshment Break & Visit Exhibits

Session 5: Gastrointestinal Malignancies

Chairs: Thomas Semrad, M.D., (UC Davis) and Anthony El-Khoueiri, M.D., (USC)

10:45 am	Keynote Lecture: Novel Approaches to the Treatment of Colorectal Carcinoma <i>Heinz-Josef Lenz, M.D., Ph.D., USC</i>
11:05 am	Question-and-Answer Session
11:10 am	New Developments in Pancreatic Cancer <i>Philip Philip, M.D., Wayne State</i>
11:25 am	Question-and-Answer Session

Session 6: Hematologic Malignancies

Chair: Brian Jonas, M.D., Ph.D., (UC Davis)

11:30 am	Drug Development in Lymphoid Malignancies: Implications for Personalized Therapy <i>Tanya Siddiqi, M.D., City of Hope</i>
11:50 am	Question-and-Answer Session
11:55 am	Non-Hodgkin Lymphoma: Current and Future Directions <i>Joseph Tuscano, M.D., UC Davis</i>

CONFERENCE AGENDA

- 12:10 pm Question-and-Answer Session
12:15pm Refreshments & Visit Exhibits
12:30 pm **Lunch Symposia (non cme)**

Session 7: Genitourinary Malignancies

Chairs: Przemyslaw Twardowski, M.D., (City of Hope), Monica Joshi, M.D., (Penn State)

- 1:15 pm Updates on Castration Resistant Prostate Cancer Therapy
David Quinn, MBBS, Ph.D., USC
1:35 pm Question-and-Answer Session
1:40 pm Updates in Renal Cell Carcinoma Drug Development
Sumanta Pal, M.D., City of Hope
1:55 pm Question-and-Answer Session

Session 8: Melanoma

Chair: Edward Newman, Ph.D., (City of Hope)

- 2:00 pm BRAF Inhibition in Melanoma
Ahmad Tarhini, M.D., University of Pittsburgh
2:15 pm Question-and-Answer Session
2:20 pm Beyond BRAF: New Innovations in Melanoma
Kim Margolin, M.D., University of Washington
2:35 pm Question-and-Answer Session

Session 9: Gynecologic Cancer

Chair: Lynda Roman, M.D. (USC)

- 2:40 pm Management of Ovarian Cancer in 2014
Robert Morgan, M.D., City of Hope
2:55 pm Question-and-Answer Session
3:00 pm New Approaches to Cervix and Endometrial Cancer
Amit Oza, M.D., Princess Margaret Hospital
3:15 pm Question-and-Answer Session
3:20 pm Adjourn
3:30 – 6:30 pm Industry Advisory Board Block (by invitation only)
7:30-10 pm CCCP Dinner (Newman Residence)

SUNDAY, AUGUST 10TH, 2014

- 6:30 am Registration, Refreshments & Visit Exhibits
7:15am – 8:00am **Breakfast Symposia (non cme)**
8:00 am Introduction
8:05 am Pre-session Survey

Session 9: Endocrine-Driven Cancers (with emphasis on Breast Cancer)

Chairs: George Somlo, M.D., (City of Hope), Primo Lara, Jr., M.D., (UC Davis)

- 8:10 am Keynote Lecture: New Approaches to Breast Cancer Based on Molecular Profiling
Helen Chew, M.D., UC Davis
8:25 am Question-and-Answer Session
8:30 am Prostate Cancer: Translating New Biologic Findings Into New Therapies
Jacek Pinski, M.D., Ph.D., USC
8:50 am Question-and-Answer Session

CONFERENCE AGENDA

SUNDAY, AUGUST 10TH, 2014 *Continued*

Session 10: Emerging Therapeutic Strategies in Oncology

- 8:55 am Keynote Lecture: New Concepts in Overcoming Drug Resistance
TBA
- 9:15 am Question-and-Answer Session
- 9:20 am Antibody-Drug Conjugates in Solid Tumors
Ulka Vaishampayan, M.D., Wayne State
- 9:35 am Question-and-Answer Session
- 9:40 am Antibody-Drug Conjugates and Peptibodies in Hematologic Malignancies
Joseph Tuscano, M.D., UC Davis
- 9:55 am Question-and-Answer Session
- 10:00 am Targeting DNA Repair in Cancer Therapeutics
Phillip Mack, Ph.D., UC Davis
- 10:15 am Question-and-Answer Session
- 10:20 am Refreshment Break & Visit Exhibits

Session 11: Integration of 'Omics and Biomarkers into Clinical Trials and Patient Care Chairs: Timothy Synold, PharmD, (City of Hope), Edward Newman, Ph.D., (City of Hope)

- 10:30 am Keynote Lecture: Personalizing Cancer Therapy: The NCI Impact and Match trials
Alice Chen, M.D., National Cancer Institute
- 10:45 am Molecular Phenotyping Platforms: What to Use and When
Philip Mack, Ph.D., UC Davis
- 10:55 am Pharmacogenomics: Clinical Applications
Timothy Synold, PharmD, City of Hope
- 11:05 am Circulating Tumor Cells: Relevance to Clinical Practice and Research
Xin Liu, M.D., Penn State
- 11:15 am Roundtable Discussion and Question and Answer Session
Theme: Best Practice Models for Biomarker and 'Omics Technology Deployment in the Clinic and in Clinical Trials

Session 12: New Agents in Development Chairs: Heinz-Josef Lenz M.D., Ph.D., (USC), Pat LoRusso (Wayne State)

- 11:30 am MEK inhibitors
Monica Joshi, M.D., Penn State
- 11:40 am HSP90 inhibitors
Anthony El-Khoueiry, M.D., USC
- 11:50 am Novel or reformulated cytotoxics (e.g., nab-paclitaxel, folate targeted agents)
Shirish Gadgeel, M.D., Wayne State
- 12:00 pm ALK inhibitors
Tianhong Li, M.D., Ph.D., UC Davis
- 12:10 pm Targeting epigenetics (Bromodomain inhibitors, HDAC inhibitors, etc)
Jonathan Riess, M.D., UC Davis
- 12:20 pm Question-and-Answer Session
- 12:30 pm Adjourn

HOTEL INFORMATION



THE WESTIN PASADENA

191 N Los Robles Avenue
Pasadena, CA 91101

Reservation: 866.837.4181

The Westin Pasadena welcomes guests with a full complement of facilities and amenities, all designed to ensure you leave feeling better than when you arrived. We prioritize convenience and simplicity with our 24-hour Business Center, where you can put tasks behind you with

ease, as well as Concierge services, for professional guidance on enjoying the best Pasadena has to offer. For reenergizing and clearing your mind, take advantage of our light-filled WestinWORKOUT® Fitness Studio and our alluring outdoor heated pool, with gorgeous views.

Enjoy some of the finest views of the San Gabriel Mountains and the Pasadena area from The Westin Pasadena, or step out to partake in the colorful spirit of downtown. Shoppers and food-lovers alike will revel in the remarkable range of options surrounding us. Just a few minutes on foot from the hotel, the Paseo Colorado features premier dining and retail outlets plus a cinema. Less than a mile away, historic Old Pasadena's charming storefronts house 200 shops plus a wide array of restaurants and night spots.

The Westin is located within walking distance of the Pacific Asia Museum areas, while the California Technical Institute, the historic Tournament of Roses house, and the Norton Simon Museum are all less than two miles away. A ten-minute drive will take you to the resplendent Huntington Library, with its extensive art collections and botanical gardens.

Golf enthusiasts will enjoy the 36-hole, William P. Bell-designed Brookside Golf Club, just a five-minute drive away. The nine-hole Eaton Canyon course is 15 minutes away in the San Gabriel foothills, and Santa Anita Park—a famous thoroughbred racetrack—is equally close by. The Rose Bowl, a world-famous sports and entertainment venue boasting beautiful greenery and cliff sides, is only five minutes away by car.

The Westin Pasadena is offering special rates during this conference of \$159 single or double room plus tax, European Plan (no meals). The cutoff date to make reservations is July 18th, 2014, after this date reservations are subject to hotel availability.

Make your hotel reservations by calling 866.837.4181 and use group code ***“CA Cancer Consortium Conference”***

CONFERENCE MANAGEMENT

MEETING EVENTS & CONFERENCE COORDINATORS, INC (MECC)

1550 S Dixie Highway Suite 202

Coral Gables, FL 33146

Telephone: 305.663.1628

Fax: 305.675.2718

Website: www.meccinc.com

Email: tvalls@meccinc.com

Register online at www.meccinc.com under upcoming events.

10th Annual California Cancer Consortium Conference

“Recent Advances and New Directions in Cancer Therapy”

August 8-10, 2014, The Westin Pasadena, Pasadena, CA

Registration Form

Name _____ Degree _____

License Number _____ State _____

Address _____

Telephone (____) _____ Fax (____) _____

Email _____

Specialty _____

TYPE OF PRACTICE:

- Private Academic
 Hospital Other

REGISTRATION FEE:

- \$175 Physician
 \$ 75 Nurse, Nurse Practitioner, Resident, Fellow,
Students, Non-physician researchers and staff
(e.g., CRAs)
 \$250 Industry Professional
 \$ 25 Per person (Saturday night dinner)

Refunds must be provided in writing prior to July 8th, 2014. A \$50 administrative charge will be deducted for all refunds prior to July 8th, after July 8th no refunds will be provided.

Enclosed is my check i/a/of \$ _____ for the registration of this conference.

I authorize MECC to charge my credit card i/a/o \$ _____ for the registration of this course using the following credit card.

Name as it appear on the card _____ Exp. Date _____

Card number _____

Authorized signature _____

**For those requiring special assistance, contact MECC
at 305.663.1628 or via email tvalls@meccinc.com no later than July 8th, 2014.**

Meetings, Events and Conference Coordinators, Inc.
P.O. Box 430376
Miami, FL 33243-0376

PRST STD
US Postage
PAID
Miami, FL
Permit No. 1429

“Recent Advances and New Directions in Cancer Therapy”
10TH ANNUAL CALIFORNIA CANCER CONSORTIUM CONFERENCE
August 8-10, 2014
The Westin Pasadena, Pasadena, CA